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Background. The role of primary immunodeficiencies (PID) in susceptibility to sepsis remains unknown. It is unclear whether 
children with sepsis benefit from genetic investigations. We hypothesized that sepsis may represent the first manifestation of un-
derlying PID. We applied whole-exome sequencing (WES) to a national cohort of children with sepsis to identify rare, predicted 
pathogenic variants in PID genes.
Methods. We conducted a multicenter, population-based, prospective study including previously healthy children aged ≥28 days 
and <17 years admitted with blood culture-proven sepsis. Using a stringent variant filtering procedure, analysis of WES data was re-
stricted to rare, predicted pathogenic variants in 240 PID genes for which increased susceptibility to bacterial infection has been reported.
Results. There were 176 children presenting with 185 sepsis episodes who underwent WES (median age, 52 months; interquar-
tile range, 15.4–126.4). There were 41 unique predicted pathogenic PID variants (1 homozygous, 5 hemizygous, and 35 heterozygous) 
found in 35/176 (20%) patients, including 3/176 (2%) patients carrying variants that were previously reported to lead to PID. The vari-
ants occurred in PID genes across all 8 PID categories, as defined by the International Union of Immunological Societies. We did not 
observe a significant correlation between clinical or laboratory characteristics of patients and the presence or absence of PID variants.
Conclusions. Applying WES to a population-based cohort of previously healthy children with bacterial sepsis detected variants 
of uncertain significance in PID genes in 1 out of 5 children. Future studies need to investigate the functional relevance of these vari-
ants to determine whether variants in PID genes contribute to pediatric sepsis susceptibility.
Keywords.  child; exome sequencing; genomics; immunodeficiency; sepsis; variant; variants of uncertain significance.
The incidence of sepsis is highest at the extremes of age: in 
the very young and the very old [1–3]. In high-income coun-
tries, 35% to 50% of pediatric sepsis deaths occur in previously 
healthy infants and children, despite access to vaccinations, 
health care, and effective antibiotics [2, 4]. Sepsis-related mor-
bidity in the absence of risk factors remains high and is as-
sociated with significant sequelae, such as amputations and 
neurodevelopmental disabilities [5]. The mechanisms under-
lying susceptibility to severe infectious diseases in otherwise 
healthy patients remain largely unknown, but epidemiological 
studies suggest a strong genetic contribution [6]. It has been 
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proposed that severe infections in childhood are more likely to 
be the manifestation of rare, single-gene disorders, compared 
with infections occurring in adults [7, 8]. Case reports anec-
dotally show that life-threatening infections of childhood may 
represent the first manifestation of primary immunodeficiency 
(PID) [8]. However, little is known about the prevalence of PID 
gene variants in patients with sepsis, and there is a lack of guid-
ance to advise on genetic or immunologic investigations after a 
first sepsis episode [9, 10].
Whole-exome sequencing (WES) has emerged as a powerful 
tool to identify disease-causing genetic variants [11, 12]. We re-
cently reported the successful application of WES in a highly 
selected cohort of pediatric sepsis cases [9]. WES has never 
been used to assess the genetic contribution to sepsis in larger 
population-based cohorts.
Although WES is insufficient to determine the functional rel-
evance of genetic variants, it enables their identification in those 
PID genes previously reported to be associated with bacterial 
infection. We hypothesized that those rare and predicted path-
ogenic genetic variations in PID genes that are associated with 
bacterial infection are more common in previously healthy chil-
dren who develop blood culture–positive, community-acquired 
sepsis, compared with genomic reference cohorts.
METHODS
Study Design
We conducted a prospective, observational, multicenter cohort 
study enrolling children presenting with blood culture–proven 
bacterial sepsis in the 10 major pediatric hospitals in Switzerland 
between 1 September 2011 and 31 December 2015. The study 
protocol and details of the Swiss Pediatric Sepsis Study have 
been reported elsewhere [13, 14]. Written informed consent for 
genetic analyses was obtained from parents or legal guardians. 
The ethical review board approved the study (Cantonal Ethics 
Committee, University of Bern, KEK-029/11).
Inclusion Criteria
Previously healthy children aged >28 days and <17 years with 
community-acquired, blood culture–proven bacterial sepsis 
due to Streptococcus pneumoniae, Staphylococcus aureus, Group 
A and B streptococcus, Neisseria meningitidis, or Haemophilus 
influenzae, as defined by 2005 pediatric sepsis consensus def-
initions [15], were eligible. These pathogens were selected be-
cause they represent the most common pathogens causing 
community-acquired sepsis in children without comorbidities.
Exclusion Criteria
Prematurely born neonates, infants <28 days (or <44 weeks of 
gestational age), and children with comorbidities, including 
any chronic inborn or acquired medical conditions, known 
primary or secondary immunodeficiency, recent trauma, sur-
gery or burns, and children with hospital-acquired infections 
(>48 hours after admission) or with pathogens other than those 
listed under the inclusion criteria were not considered for WES.
Whole-exome Sequencing, Read Mapping, Variant Calling, and Variant 
Annotation
Blood samples were collected and processed as reported else-
where [9]. WES was performed on Illumina HiSeq 2500 at 
the Lausanne Genomic Technology Facility (Supplementary 
Methods; Supplementary Tables 1, 2 and 3). Sequencing reads 
were mapped to the human reference genome hg19 using 
BWA-MEM v0.7.15 [16, 17]. The Genome Analysis ToolKit 
v3.8 Sequence Data Processing Tools and Variant Discovery 
Tools were used according to best practices [18, 19]. These 
included base quality score recalibration and per-sample, si-
multaneous calling of single nucleotide variants and small in-
sertions and deletions (indels) with the HaplotypeCaller tool, 
followed by joint genotyping and quality filtering (only variants 
with genotype quality >100 and read depth >20 were kept for 
a downstream analysis). Genetic and functional annotation 
included putative effect predictions for Sequence Ontology 
terms, putative loss-of-function predictions, and effect predic-
tions from multiple algorithms. Each variant was annotated 
with information on minor allele frequency (MAF) in several 
public databases, including the 1000 Genomes project Phase 1 
(n = 1092), the NHLBI exome sequencing project (n = 7520), 
the Genome Aggregation Database (gnomAD; n = 138632), and 
519 in-house control exomes.
Filtering and Identification of Candidate Genomic Variants in Primary 
Immunodeficiency Genes
Analyses were restricted to nonsynonymous, exonic variants 
that are rare in the general population (MAF <0.01 for homo-
zygous/hemizygous and <0.0001 for heterozygous variants in 
the gnomAD database). We also filtered out variants with a 
MAF >0.01 in our in-house exome database. We restricted the 
analysis to variants in 240 PID genes previously reported to be 
associated with bacterial disease as defined by the International 
Union of Immunological Societies (IUIS) [20]. We further pri-
oritized variants by filtering for predicted pathogenicity, keeping 
only variants with a putative deleterious impact according to 
the Combined Annotation Dependent Depletion v1.3 score 
[21], resulting in putatively pathogenic variants. For every pu-
tatively pathogenic variant, PubMed entries between 1.1.1970 
and 30.6.2019 were searched for reports on patients with PID 
and bacterial infections carrying the exact variant. The study did 
not include functional validation. Therefore, the filtered rare and 
predicted pathogenic variants in the selected PID genes were la-
belled as variants of uncertain significance (VUS).
Statistical Analysis
Descriptive statistics are presented as median and interquartile 
ranges for continuous variables and frequencies and percent-
ages for categorical variables. We used the χ 2 test of proportions 
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and the Wilcoxon nonparametric rank sum test to compare 
subgroups. We considered a 2-sided P value of <.05 as signif-
icant. Analyses and graphs were done using R (R Core Team, 




During the study period, out of 1275 blood culture–proven 
sepsis episodes, 383 occurred in 380 previously healthy children 
(Figure 1). Streptococcus pneumoniae, S. aureus, Group A and 
B streptococcus, N. meningitidis, and H. influenzae accounted 
for 271/383 (70%) sepsis episodes. There were 94 patients ex-
cluded, predominantly because of a lack of consent or lack of 
access to DNA. There was 1 case of H.  influenzae B sepsis in 
an unvaccinated child that was excluded. The final WES co-
hort consisted of 176 children, including 8 (5%) with recurrent 
bacterial sepsis (Table  1). Of these, 38.64% of patients devel-
oped organ dysfunction and 37.5% required pediatric intensive 
care unit (PICU) admission for sepsis. Of the 176 children, 5 
(2.8%) died.
Identification of Putatively Causative Primary Immunodeficiency Variants
WES was successfully performed in all 176 study participants. In 
total, 8 463 144 variants were identified. After filtering based on 
the predicted function impact, predicted pathogenicity, and MAF, 
35 966 variants were retained (Supplementary Figure 1). We then 
restricted analyses to rare variants in 240 PID genes known to 
be associated with bacterial infection: 41 unique rare and pre-
dicted pathogenic VUS were identified in 35 out of 176 partici-
pants (20%) across 24 PID genes (Table 2; Supplementary Figure 
2). Biallelic (homozygous) variants were found in 1 participant in 
1 gene, X-linked variants were found in 5 participants in 5 genes, 
and monoallelic variants were found in 35 study participants 
in 18 genes. In 30/35 patients (86%), only 1 variant was found, 
whereas in 5/35 (14%) patients, 2 or 3 variants were discovered. 
Out of the 41 variants, 3 exact variants in 3/176 participants (2%) 
were identical to previously reported variants from patients with 
a PID phenotype with a bacterial infection (Table 3).
Characterization and Distribution of Primary Immunodeficiency Gene 
Variants in Children with Sepsis
The identified variants were distributed across all PID groups 
(Table 2; Supplementary Figures 2 and 3; Supplementary Table 
4) [20]. They were most commonly found in CHD7 (n = 6 pa-
tients) and SAMD9, TCF3, and BACH3 (n  =  3 each). The 3 
previously reported PID variants related to combined immuno-
deficiencies with associated symptoms, phagocyte defects, and 
complement defects (Table 3).
We did not observe any association of variants with specific 
pathogens or a focus of infection (Table 1; P > .10). They were 
found in 13 out of 54 patients with a S. pneumoniae infection 
(24%), in 7 out of 44 patients with a S. aureus infection (16%), 
in 6 out of 33 patients with a Group A streptococcal infection 
(18%), in 4 out of 17 patients with a Group B streptococcal in-
fection (24%), in 2 out of 16 patients with an N. meningitidis in-
fection (13%), and in 3 out of 12 patients with an H. influenzae 
infection (25%; Table  1; Supplementary Figure 3). There was 
no significant difference in the proportion of children found to 
carry PID variants between children <2 years (12/56, 21%) and 
>2 years of age (23/120; 19%; P = .8; Figure 2; Supplementary 
Figure 4). No significant differences were observed when com-
paring the proportion of children with and without different 
PID variants in relation to the presence of organ dysfunction, 
PICU admission, the frequency of leukopenia, or the maximum 
C-reactive protein level measured during sepsis (Table  1). 
Variants were found in 4/8 (50%) patients with recurrent 
sepsis, versus 31/168 (18%) in children without recurrent sepsis 
(P = .051, Fisher test).
DISCUSSION
In this prospective, population-based cohort of previously 
healthy children presenting with blood culture–proven bacte-
rial sepsis, rare variants in genes previously reported to lead 
to PID associated with bacterial infections were substantially 
more common than previously assumed. It is important to note 
that the variants identified in our study are predicted but not 
functionally confirmed to affect gene functions and lead to 
immunodeficiency. Therefore, they must be considered VUS. 
Importantly, around 1 out of 50 (3/176; 2%) children with 
community-acquired sepsis that underwent WES carried exact 
variants that have been previously shown to result in PID asso-
ciated with bacterial infections, which is higher than the esti-
mated prevalence of PID in the population [22]. The variants 
identified in PID genes were distributed across all main IUIS 
categories [20]. We did not observe specific patterns in terms of 
pathogens, severity, inflammatory markers, or age at presenta-
tion that were associated with the likelihood of detecting such 
variants. These VUS in genes previously linked to susceptibility 
to bacterial infections within the context of clearly defined PID 
were found in otherwise apparently healthy children with bac-
terial sepsis. This finding may be explained either by a lack of 
functional relevance or by pleiotropy. WES represents a prom-
ising first step to investigate children with sepsis for potentially 
underlying PID. Future studies should combine WES with 
in-depth functional assays.
Understanding why a minority of children become very ill 
in the course of an infection remains among the mysteries of 
sepsis and may harbor clues for future targeted interventions 
[23]. Casanova et  al [8] previously stated the hypothesis that 
life-threatening infections of childhood may represent the first 
manifestation of PID. The identification of PID in children with 
sepsis due to community-acquired bacteria has been reported 
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in highly selected cases caused by Pseudomonas aeruginosa [9, 
24, 25] or S. pneumoniae. A French study that investigated 163 
children with pneumococcal disease using conventional im-
munologic screening reported underlying PID in 10% of cases 
[26], with a higher proportion of PID found in children >2 years 
of age. Monogenic diseases resulting in PID have been shown 
to be associated with selected invasive bacterial infections, in-
cluding Group B streptococcal and staphylococcal infections 
[27]. Several nonconventional PID, such as IRAK-4, MyD88, and 
TIRAP deficiencies [28–30], are characterized by incomplete 
Figure 1. Enrollment flow diagram of WES cohort. Patients undergoing WES were previously healthy children with blood culture–proven sepsis caused by S. pneumoniae, 
S.  aureus, Group A  streptococcus, GBS, N.  meningitidis, and H.  influenzae. Abbreviations: CVC, central venous line; d, days; E.  cloacae, Enterobacter cloacae; E.  coli, 
Escherichia coli; E.  faecium, Enterococcus faecium; GA, gestational age; GBS, Group B streptococcus; H.  influenzae, Haemophilus influenzae; N. meningitidis, Neisseria 
meningitidis; P. aeruginosa, Pseudomonas aeruginosa; PCR, polymerase chain reaction; S. aureus, Staphylococcus aureus; S. pneumoniae, Streptococcus pneumoniae; SPSS, 
Swiss Pediatric Sepsis Study; w, weeks; WES, whole-exome sequencing.
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Table 1. Demographic and Clinical Characteristics 
All Children,  
n = 176, 100%
Children Without PID 
Variants,  
n = 141, 80%
Children with PID  
Variants of Uncertain Significance, 
n = 35, 20%
Children with Previously  
Reported PID Variant,  
n = 3, 2%
Demographics
 Age at sepsis onset, months 51.9 (15.3–126.5) 54.5 (15.4–127.2) 40.2 (9.1–111.7) 128.3 (27.5–170.4)
 Age group
  28–365 days 41 (23%) 32 (23%) 9 (26%) 1 (33%)
  1–4 years 53 (30%) 42 (30%) 11 (31%) …
  5–9 years 35 (20%) 28 (20%) 7 (20%) …
  10–16 years 47 (27%) 39 (28%) 8 (23%) 2 (67%)
 Male 112 (64%) 87 (62%) 25 (71%) 2 (67%)
 Ethnicitya
  Caucasian 159 (90%) 127 (90%) 32 (91%) 3 (100%)
  Asian 4 (2%) 3 (2%) 1 (3%) …
  African 4 (2%) 4 (3%) … …
  other 3 (2%) 3 (2%) … …
Site of infection
 Primary bloodstream infection 22 (12%) 19 (13%) 3 (9%) …
 Pneumonia 47 (27%) 39 (28%) 8 (23%) 1 (33%)
 Bone and joint infection 37 (21%) 30 (21%) 7 (20%) 1 (33%)
 Central nervous system infection 33 (19%) 23 (16%) 10 (29%) 1 (33%)
 Skin and soft tissue infection 15 (9%) 12 (9%) 3 (9%) …
 Ear, nose, and throat infection 9 (5%) 6 (4%) 3 (9%) …
 Toxic shock syndrome 4 (2%) 4 (3%) … …
 Gastrointestinal system infection 2 (1%) 2 (1%) … …
 Urinary tract infection 1 (1%) 1 (1%) … …
 Other specific infection type 6 (3%) 5 (4%) 1 (3%) …
Pathogens
 Gram-positive bacteria 148 (84%) 118 (84%) 30 (86%) 3 (100%)
  Streptococcus pneumoniae 54 (31%) 41 (29%) 13 (37%) 2 (67%)
  Staphylococcus aureus 44 (25%) 37 (26%) 7 (20%) 1 (33%)
  Group A streptococci 33 (19%) 27 (19%) 6 (17%) …
  Group B streptococci 17 (10%) 13 (9%) 4 (11%) …
 Gram-negative bacteria 28 (16%) 23 (16%) 5 (14%) …
  Neisseria meningitidis 16 (9%) 14 (10%) 2 (6%) …
  Haemophilus influenzae 12 (7%) 9 (6%) 3 (9%) …
Severity of sepsis
 Organ dysfunction
  No organ dysfunction present 108 (61%) 89 (63%) 19 (54%) 1 (33%)
  ≥1 organ dysfunction 68 (39%) 52 (37%) 16 (46%) 2 (67%)
 C-reactive protein, mg/Lb 192 (94–260) 186 (95–266) 198 (88–237) 192 (165–200)
 Leukopenia presentc 30 (17%) 21 (15%) 9 (26%) 1 (33%)
 PICU/NICU admission 66 (38%) 53 (38%) 13 (37%) 2 (67%)
 Length of PICU stay, days 5 (2–9) 4 (2–9) 7 (2–12) 19 (2–36)
 Length of hospital stay after 
sepsis onset, days
10 (7–15) 10 (7–15) 11 (7–15) 10 (6–55)
 Invasive ventilation 36 (20%) 29 (21%) 7 (20%) 1 (33%)
 Inotrope requirement 39 (22%) 31 (22%) 8 (23%) 2 (67%)
 Case fatality 6 (3%) 5 (4%) 1 (3%) …
Data are from children with blood culture–proven bacterial sepsis in relation to whole-exome sequencing findings of putatively pathogenic variants in known PID genes. Characteristics of 
children without a PID variant (n = 141) are compared to children in whom a PID variant of uncertain significance was found (n = 35, including novel and previously reported PID variants) and 
children in whom a previously reported PID variant was found (n = 3). Categorical variables are given as frequencies and percentages and continuous variables as median and interquartile 
range. Column percentages are given. Percentages are based upon available data for each variable.
Abbreviations: NICU, neonatal intensive care unit; PICU, pediatric intensive care unit; PID, primary immunodeficiency.
aData not available in 6 episodes. 
bData not available in 9 episodes. 
cData not available in 3 episodes. 
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penetrance and variable pathogen specificity. The effects of some 
PID on increased susceptibility to infection may decrease with 
age if patients survive infections during childhood [28]. In our 
study, we did not find any association between the presence of 
PID VUS and increased disease severity, measured by a need for 
PICU admission, the number of organ dysfunctions, or septic 
shock [31]. Blood culture–proven sepsis represents an extreme 
phenotype from an evolutionary perspective, given the high fa-
tality rate of bacteremia in the absence of antimicrobial therapy. 
In contrast, extreme phenotypes, as defined by contemporary 
medicine where intensive care support is available, are subject 
to different host genetics, pathogens, and environmental factors. 
Importantly, the time to antibiotics represents a major determi-
nant of severity [4, 32], and the specific setting in Switzerland 
has to be considered, including a low proportion of socioeco-
nomically disadvantaged children and a high-density pediatric 
hospital network, potentially resulting in earlier treatment.
Children requiring life support due to severe infections in 
PICUs are currently not routinely investigated for the presence 
of PIDs. No specific guidelines exist for clinicians when facing 






Focus Gene HGVS (protein) Inheritance
Read  
Depth
Frequencies in  
GnomAD PubMed ID
CID+ M 223 SP CNS WAS E131K (p.Glu131Lys) XL 25 0,00260066 Missense variant (15284122)
PD M 3905 SA Bone/joint CYBB G364R (p.Gly364Arg) XL 40 0,00394664 Missense variant (10089913)
CD F 5443 SP Pneumonia CFH P503A (p.Pro503Ala) AD 176 1,63E-05 Missense variant (24906858)
Data are for variants found in children with blood culture–proven sepsis. Host and pathogen characteristics are shown of the sepsis episodes (n = 3) where a patient was found to carry a 
previously reported PID variant associated with bacterial infection, as are details of the identified variants.
Abbreviations: AD, autosomal-dominant; CD, complement defects; CID+, combined immunodeficiencies with associated symptoms; CNS, central nervous system infection; F, female; 
gnomAD, Genome Aggregation Database; HGVS, Human Genome Variation Society; IUIS, International Union of Immunological Societies; M, male; PD, phagocyte defects; PID, primary 
immunodeficiency; SA, Staphylococcus aureus; SP, Streptococcus pneumoniae; XL, X-linked.
Figure 2. Number of previously healthy children with blood-culture-proven sepsis in relation to age and severity at presentation. Children testing positive for a rare VUS 
associated with primary immunodeficiency are shown in blue; in comparison, children where no VUS associated with primary immunodeficiency was found are shown in 
light gray. Abbreviations: GAS, group A streptococcus; GBS, Group B streptococcus; HI, Haemophilus influenzae; NM, Neisseria meningitidis; SA, Staphylococcus aureus; SP, 
Streptococcus pneumoniae; VUS, variant of uncertain significance; y, years.
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the question of whether a child with sepsis may harbor a PID 
[10]. There is a need for studies defining indications for PID 
investigations in children with sepsis, coupled with increased 
education and awareness of pediatric intensivists, infectious di-
sease specialists, and pediatricians on the topic. Selection rules 
based on pathogens, severity, or a history of familial reoccur-
rence alone could be inaccurate, as demonstrated by the ab-
sence of clear patterns in our study. In addition, commonly used 
immunological investigations, such as the measurement of total 
and specific immunoglobulin, complement protein concentra-
tions, and basic lymphocyte populations, will miss a substantial 
proportion of PID in comparison to WES. Importantly, recog-
nizing and accurately diagnosing underlying PID in children 
presenting with sepsis is important given the risk of recurrence 
of infection, with potentially fatal but preventable outcomes [9]. 
The challenges in interpreting the findings of our study high-
light that while next-generation sequencing (NGS) represents 
a promising diagnostic tool in children with sepsis, NGS-based 
genetic testing must be followed by specifically indicated func-
tional tests if WES is to be considered as a routine diagnostic 
approach. Validation of the findings will require immunological 
follow-up of the study cohort, including assessments of subse-
quent invasive infections. Unfortunately, the study approval was 
restricted to singleton testing. Future studies embarking on un-
ravelling the genetic contribution to childhood sepsis need to 
incorporate functional analyses both during disease and (if the 
patient survives) during recovery, including extended investiga-
tions of parents and siblings, as indicated. In view of our find-
ings of a high number of VUS across all IUIS categories, the 
availability of immune-phenotyping platforms to assess a broad 
range of immunological pathways carries strong promise [33].
NGS has been successfully applied both to discover novel 
disease-causing gene variants and to obtain a molecular di-
agnosis of monogenic conditions [34, 35], and may be cost 
effective in comparison to standard genetic diagnostic proced-
ures [35]. Yet, as a result of the increasing number of patients 
undergoing WES [11, 36], the field of clinical immunology is 
rapidly evolving, and expanding cohorts demonstrate consid-
erable variability of the phenotypes. The mechanisms under-
lying incomplete penetrance and variable expressivity remain 
mostly unexplained and are likely complex, as demonstrated by 
the recent discovery of the role of anti-lipoteichoic acid (LTA) 
antibody deficiencies in patients with a TIRAP deficiency [27]. 
We applied stringent filtering criteria including several control 
cohorts, and restricted analyses to rare variants predicted to 
have functional impacts in genes known to lead to PID pheno-
types associated with bacterial infection. Despite this approach, 
confirming that rare VUS identified by WES are pathogenic 
remains a challenge [12, 37]. Rare variants in genes previously 
demonstrated to result in Mendelian disease may also con-
tribute to the risks of infection through complex and polygenic 
mechanisms [38]. A  recent landmark study using electronic 
health record–based phenotype risk scores in large, genotyped 
cohorts identified a substantial number of undiagnosed patients 
harboring rare variants and phenotypes related to unrecognized 
Mendelian diseases [39]. A  combination of international co-
horts will be required to provide the power for the statistical 
validation of enriched variants or pathways, or to test the hypo-
thesis that complex/polygenic predispositions could also play a 
role in human susceptibility to sepsis.
Despite these challenges, our findings are based on a high-
quality, prospective, population-based study restricted to the 
gold standard of invasive infection (bacteraemia). The design 
of this national cohort minimized an inclusion bias in com-
parison to the majority of immunologic studies, commonly 
based on highly selected referral patients with severe or recur-
rent disease. We carefully excluded children with underlying 
comorbidities, in order to focus on community-acquired sepsis 
in children that were apparently healthy before hospital admis-
sion. We acknowledge that this may have led to the exclusion of 
children harboring PID associated with a congenital disease or 
syndromes. We restricted WES to the most common pathogens 
causing community-acquired sepsis [14], and acknowledge that 
PIDs potentially may be more common in children presenting 
with unusual bacterial pathogens.
Our study has several additional limitations. Most importantly, 
we did not functionally verify the pathogenicity of the variants 
identified in PID genes. While we used stringent filtering and 
pathogenicity prediction criteria aligned with best practices, and 
assessed whether variants had been previously demonstrated to 
lead to PID with bacterial infection, their pathogenicity has not 
been demonstrated, thus resulting in a possible overestimation 
of the proportion of PID-related sepsis. Functional validation 
in our and other independent cohorts will be required to define 
the true proportion of PID causing sepsis in children. Second, 
we only focused on those PID genes previously demonstrated to 
be associated with bacterial infection, which may have led to the 
exclusion of causative variants, thereby resulting in an underesti-
mation of the proportion of PID-related sepsis. In addition, the 
genetic backgrounds for several PID, mainly disorders affecting 
antibody production, are unknown, which may again result in 
an underestimation of PID. Considering the rapid expansion of 
recently identified novel PID, it is thus also likely that a subset 
of patients may harbor disease-conferring yet unidentified novel 
PID. Experimental validation to define the causal relationship be-
tween genotype and phenotype is crucial during the investigation 
of novel PID candidates. Third, an intrinsic limitation in WES is 
the inability to detect deep intronic and intergenic genetic vari-
ants. Finally, we did not assess the microbiological factors deter-
mining pathogen virulence, such as toxins.
In conclusion, applying WES to a population-based cohort 
of previously healthy children presenting with bacterial sepsis 
allowed for the detection of VUS in previously reported PID 
genes in a substantial proportion of sepsis cases. Our study 
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explores the possible contribution of host genetic variations to 
sepsis susceptibility. Future studies combining NGS with func-
tional testing are required to validate whether unrecognized 
PIDs contribute significantly to sepsis at the populational level. 
Our findings indicate an urgent need for evidence-based re-
commendations on the optimal selection of children with sepsis 
for genetic and functional investigations to identify PIDs.
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